• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.肺炎链球菌中赋予对大环内酯类、克林霉素、链阳菌素和替利霉素耐药性的核糖体突变的多样性。
Antimicrob Agents Chemother. 2002 Jan;46(1):125-31. doi: 10.1128/AAC.46.1.125-131.2002.
2
Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.23S核糖体RNA和核糖体蛋白L4中的突变导致了在体外经大环内酯类药物传代筛选出的肺炎球菌菌株产生耐药性。
Antimicrob Agents Chemother. 2000 Aug;44(8):2118-25. doi: 10.1128/AAC.44.8.2118-2125.2000.
3
Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.两种新型大环内酯类药物GW 773546和GW 708408与红霉素、阿奇霉素、克拉霉素、克林霉素和泰利霉素相比的抗肺炎球菌活性。
Antimicrob Agents Chemother. 2004 Nov;48(11):4103-12. doi: 10.1128/AAC.48.11.4103-4112.2004.
4
Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study.来自1999 - 2000年PROTEKT研究的肺炎链球菌临床分离株中核糖体突变导致的大环内酯类耐药性
Antimicrob Agents Chemother. 2003 Jun;47(6):1777-83. doi: 10.1128/AAC.47.6.1777-1783.2003.
5
In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae.肺炎支原体对大环内酯类及相关抗生素耐药性的体外筛选与鉴定
Antimicrob Agents Chemother. 2004 Feb;48(2):460-5. doi: 10.1128/AAC.48.2.460-465.2004.
6
Time-kill study of the activity of telithromycin against macrolide-resistant Streptococcus pneumoniae Isolates with 23S rRNA mutations and changes in ribosomal proteins L4 and L22.泰利霉素对具有23S rRNA突变及核糖体蛋白L4和L22改变的大环内酯类耐药肺炎链球菌分离株活性的时间杀菌研究
Antimicrob Agents Chemother. 2005 Jul;49(7):3011-3. doi: 10.1128/AAC.49.7.3011-3013.2005.
7
High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae.肺炎链球菌实验室诱导突变体中的高水平替利霉素耐药性。
J Antimicrob Chemother. 2003 Sep;52(3):345-53. doi: 10.1093/jac/dkg348. Epub 2003 Aug 13.
8
Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).在加拿大呼吸道病原体药敏试验(CROSS,1998 - 2004年)的6年期间分离出的肺炎链球菌中的大环内酯类耐药机制。
J Antimicrob Chemother. 2007 Oct;60(4):733-40. doi: 10.1093/jac/dkm273. Epub 2007 Aug 2.
9
Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis.23S rRNA中的突变导致人型支原体和解脲脲原体对大环内酯类药物产生固有耐药性,以及人型支原体对大环内酯类药物产生获得性耐药性。
Antimicrob Agents Chemother. 2002 Oct;46(10):3142-50. doi: 10.1128/AAC.46.10.3142-3150.2002.
10
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.来自东欧和北美的肺炎链球菌临床菌株中两种新的大环内酯类耐药机制。
Antimicrob Agents Chemother. 2000 Dec;44(12):3395-401. doi: 10.1128/AAC.44.12.3395-3401.2000.

引用本文的文献

1
Hydration conditions as a critical factor in antibiotic-mediated bacterial competition outcomes.水合条件作为抗生素介导的细菌竞争结果的关键因素。
Appl Environ Microbiol. 2025 Jan 31;91(1):e0200424. doi: 10.1128/aem.02004-24. Epub 2024 Dec 23.
2
The Role of the Skin Microbiome in Acne: Challenges and Future Therapeutic Opportunities.皮肤微生物组在痤疮中的作用:挑战与未来治疗机遇。
Int J Mol Sci. 2024 Oct 24;25(21):11422. doi: 10.3390/ijms252111422.
3
Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology.克林霉素:一份全面的现状报告,重点关注其在皮肤科的应用
J Clin Aesthet Dermatol. 2024 Aug;17(8):29-40.
4
Antimicrobial Resistance in Livestock: A Serious Threat to Public Health.家畜中的抗菌素耐药性:对公众健康的严重威胁。
Antibiotics (Basel). 2024 Jun 13;13(6):551. doi: 10.3390/antibiotics13060551.
5
Effect of erythromycin residuals in food on the development of resistance in : an study in .食品中红霉素残留对耐药性发展的影响:在中国的一项研究。
PeerJ. 2024 May 28;12:e17463. doi: 10.7717/peerj.17463. eCollection 2024.
6
Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease.克林霉素用于治疗皮肤病的科学依据和临床基础
Antibiotics (Basel). 2024 Mar 17;13(3):270. doi: 10.3390/antibiotics13030270.
7
Genetic diversity of macrolides resistant Staphylococcus aureus clinical isolates and the potential synergistic effect of vitamins, C and K.耐大环内酯类金黄色葡萄球菌临床分离株的遗传多样性及维生素 C 和 K 的潜在协同作用。
BMC Microbiol. 2024 Jan 20;24(1):30. doi: 10.1186/s12866-023-03169-1.
8
Structure Elucidation and Interaction Dynamics of MefA-MsrD Efflux Proteins in : Impact on Macrolide Susceptibility.MefA-MsrD外排蛋白的结构解析与相互作用动力学:对大环内酯类药物敏感性的影响
ACS Omega. 2023 Oct 10;8(42):39454-39467. doi: 10.1021/acsomega.3c05210. eCollection 2023 Oct 24.
9
New Resistance Mutations Linked to Decreased Susceptibility to Solithromycin in Streptococcus pneumoniae Revealed by Chemogenomic Screens.通过化学生物基因组筛选发现肺炎链球菌中新的耐药突变与索利霉素敏感性降低有关。
Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0039523. doi: 10.1128/aac.00395-23. Epub 2023 Jul 6.
10
Genomic insights into antibiotic resistance and mobilome of lactic acid bacteria and bifidobacteria.对乳酸菌和双歧杆菌的抗生素耐药性和移动元件的基因组见解。
Life Sci Alliance. 2023 Feb 13;6(4). doi: 10.26508/lsa.202201637. Print 2023 Apr.

本文引用的文献

1
Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae.肺炎链球菌中导致对16元大环内酯类和链阳菌素耐药的23S rRNA突变。
Antimicrob Agents Chemother. 2001 Jan;45(1):319-23. doi: 10.1128/AAC.45.1.319-323.2001.
2
Macrolide resistance conferred by base substitutions in 23S rRNA.23S核糖体RNA碱基置换导致的大环内酯类耐药性。
Antimicrob Agents Chemother. 2001 Jan;45(1):1-12. doi: 10.1128/AAC.45.1.1-12.2001.
3
Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.来自东欧和北美的肺炎链球菌临床菌株中两种新的大环内酯类耐药机制。
Antimicrob Agents Chemother. 2000 Dec;44(12):3395-401. doi: 10.1128/AAC.44.12.3395-3401.2000.
4
The structural basis of ribosome activity in peptide bond synthesis.核糖体在肽键合成中活性的结构基础。
Science. 2000 Aug 11;289(5481):920-30. doi: 10.1126/science.289.5481.920.
5
The complete atomic structure of the large ribosomal subunit at 2.4 A resolution.2.4埃分辨率下大核糖体亚基的完整原子结构。
Science. 2000 Aug 11;289(5481):905-20. doi: 10.1126/science.289.5481.905.
6
Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.23S核糖体RNA和核糖体蛋白L4中的突变导致了在体外经大环内酯类药物传代筛选出的肺炎球菌菌株产生耐药性。
Antimicrob Agents Chemother. 2000 Aug;44(8):2118-25. doi: 10.1128/AAC.44.8.2118-2125.2000.
7
Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA.通过与23S rRNA的结构域II进行替代性药物相互作用,可增强大环内酯-酮内酯对MLS耐药核糖体的抑制作用。
Mol Microbiol. 2000 Apr;36(1):183-93. doi: 10.1046/j.1365-2958.2000.01841.x.
8
Crystal structure of ribosomal protein L4 shows RNA-binding sites for ribosome incorporation and feedback control of the S10 operon.核糖体蛋白L4的晶体结构显示了核糖体掺入的RNA结合位点以及S10操纵子的反馈控制。
EMBO J. 2000 Mar 1;19(5):807-18. doi: 10.1093/emboj/19.5.807.
9
In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae.肺炎链球菌对泰利霉素(HMR 3647)、四种大环内酯类药物、克林霉素和普那霉素的体外耐药性发展
Antimicrob Agents Chemother. 2000 Feb;44(2):414-7. doi: 10.1128/AAC.44.2.414-417.2000.
10
Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants.大环内酯类及大环内酯-林可酰胺-链阳菌素B耐药决定簇的命名法。
Antimicrob Agents Chemother. 1999 Dec;43(12):2823-30. doi: 10.1128/AAC.43.12.2823.

肺炎链球菌中赋予对大环内酯类、克林霉素、链阳菌素和替利霉素耐药性的核糖体突变的多样性。

Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.

作者信息

Canu Annie, Malbruny Brigitte, Coquemont Maëlle, Davies Todd A, Appelbaum Peter C, Leclercq Roland

机构信息

UFR des Sciences Pharmaceutiques, Caen, France.

出版信息

Antimicrob Agents Chemother. 2002 Jan;46(1):125-31. doi: 10.1128/AAC.46.1.125-131.2002.

DOI:10.1128/AAC.46.1.125-131.2002
PMID:11751122
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC126998/
Abstract

Mechanisms of resistance were studied in 22 macrolide-resistant mutants selected in vitro from 5 parental strains of macrolide-susceptible Streptococcus pneumoniae by serial passage in various macrolides (T. A. Davies, B. E. Dewasse, M. R. Jacobs, and P. C. Appelbaum, Antimicrob. Agents Chemother., 44:414-417, 2000). Portions of genes encoding ribosomal proteins L22 and L4 and 23S rRNA (domains II and V) were amplified by PCR and analyzed by single-strand conformational polymorphism analysis to screen for mutations. The DNA sequences of amplicons from mutants that differed from those of parental strains by their electrophoretic migration profiles were determined. In six mutants, point mutations were detected in the L22 gene (G95D, P99Q, A93E, P91S, and G83E). The only mutant selected by telithromycin (for which the MIC increased from 0.008 to 0.25 microg/ml) contained a combination of three mutations in the L22 gene (A93E, P91S, and G83E). L22 mutations were combined with an L4 mutation (G71R) in one strain and with a 23S rRNA mutation (C2611A) in another strain. Nine other strains selected by various macrolides had A2058G (n = 1), A2058U (n = 2), A2059G (n = 1), C2610U (n = 1), and C2611U (n = 4) mutations (Escherichia coli numbering) in domain V of 23S rRNA. One mutant selected by clarithromycin and resistant to all macrolides tested (MIC, >32 microg/ml) and telithromycin (MIC, 4 microg/ml) had a single base deletion (A752) in domain II. In six remaining mutants, no mutations in L22, L4, or 23S rRNA could be detected.

摘要

通过在各种大环内酯类药物中连续传代,从5株大环内酯类敏感的肺炎链球菌亲本菌株中体外筛选出22株大环内酯类耐药突变体,对其耐药机制进行了研究(T.A.戴维斯、B.E.德瓦斯、M.R.雅各布斯和P.C.阿佩尔鲍姆,《抗菌药物与化疗》,44:414 - 417,2000年)。通过聚合酶链反应(PCR)扩增编码核糖体蛋白L22和L4以及23S rRNA(结构域II和V)的基因片段,并通过单链构象多态性分析进行分析,以筛选突变。对电泳迁移图谱与亲本菌株不同的突变体扩增子的DNA序列进行了测定。在6个突变体中,在L22基因中检测到点突变(G95D、P99Q、A93E、P91S和G83E)。唯一一株被泰利霉素筛选出的突变体(其MIC从0.008增加到0.25μg/ml)在L22基因中含有三个突变的组合(A93E、P91S和G83E)。L22突变在一株中与L4突变(G71R)组合,在另一株中与23S rRNA突变(C26A)组合。其他9株被各种大环内酯类药物筛选出的菌株在23S rRNA的结构域V中具有A2058G(n = 1)、A2058U(n = 2)、A2059G(n = 1)、C2610U(n = 1)和C2611U(n = 4)突变(大肠杆菌编号)。一株被克拉霉素筛选出且对所有测试大环内酯类药物(MIC,>32μg/ml)和泰利霉素(MIC,4μg/ml)耐药的突变体在结构域II中有一个单碱基缺失(A752)。在其余6个突变体中,未检测到L22、L4或23S rRNA的突变。